RA
COLL icon

Royce & Associates’s Collegium Pharmaceutical COLL Stock Holding History

Royce & Associates’s Portfolio COLL Stock Details COLL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.02M Buy
272,786
+21,633
+9% +$916K 0.09% 360
2025
Q4 		$11.6M Sell
251,153
-54,987
-18% -$2.3M 0.12% 262
2025
Q3 		$10.7M Buy
306,140
+328
+0.1% +$11.4K 0.11% 282
2025
Q2 		$9.04M Buy
305,812
+3,210
+1% +$91.6K 0.09% 314
2025
Q1 		$9.03M Sell
302,602
-36,927
-11% -$1.13M 0.1% 309
2024
Q4 		$9.73M Buy
339,529
+33,674
+11% +$1.11M 0.09% 330
2024
Q3 		$11.8M Buy
305,855
+4,966
+2% +$177K 0.11% 274
2024
Q2 		$9.69M Buy
300,889
+12,180
+4% +$422K 0.09% 319
2024
Q1 		$11.2M Buy
288,709
+145,626
+102% +$5.09M 0.1% 295
2023
Q4 		$4.4M Buy
143,083
+121,853
+574% +$3.05M 0.04% 518
2023
Q3 		$474K Buy
+21,230
New +$484K ﹤0.01% 818
2023
Q1 		– Sell
-14,477
Closed -$336K – 918
2022
Q4 		$336K Sell
14,477
-13,843
-49% -$279K ﹤0.01% 858
2022
Q3 		$454K Sell
28,320
-431,923
-94% -$7.62M 0.01% 829
2022
Q2 		$8.16M Buy
460,243
+168,989
+58% +$2.84M 0.08% 341
2022
Q1 		$5.93M Sell
291,254
-32,632
-10% -$617K 0.05% 512
2021
Q4 		$6.05M Buy
323,886
+148,377
+85% +$2.89M 0.05% 519
2021
Q3 		$3.46M Buy
+175,509
New +$3.8M 0.03% 654
2020
Q1 		– Sell
-1,421
Closed -$29K – 1157
2019
Q4 		$29K Sell
1,421
-1,060
-43% -$17.7K ﹤0.01% 1085
2019
Q3 		$28K Buy
2,481
+1,013
+69% +$11.6K ﹤0.01% 1100
2019
Q2 		$19K Buy
1,468
+373
+34% +$4.99K ﹤0.01% 1117
2019
Q1 		$17K Buy
+1,095
New +$17.5K ﹤0.01% 1131
2018
Q3 		– Sell
-138,000
Closed -$3.29M – 1185
2018
Q2 		$3.29M Sell
138,000
-32,000
-19% -$787K 0.02% 710
2018
Q1 		$4.34M Buy
170,000
+33,000
+24% +$786K 0.03% 613
2017
Q4 		$2.53M Buy
+137,000
New +$1.96M 0.02% 791

Other funds holding COLL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Royce & Associates's COLL Position: Q1 2026 in Review

Royce & Associates increased its Collegium Pharmaceutical (COLL) stake by 8.6% in Q1 2026, buying an estimated $916K and bringing the position to 272,786 shares worth $9.02M. The position accounts for 0.09% of the portfolio, ranked #360.

Royce & Associates first reported a position in COLL in Q4 2017 and has held it in 24 quarters since. The position peaked at $11.8M in Q3 2024. 266 funds tracked by Wall St. Rank hold COLL as of Q1 2026.

  • Royce & Associates held 272,786 shares of Collegium Pharmaceutical worth $9.02M as of Q1 2026.
  • Royce & Associates bought 21,633 Collegium Pharmaceutical shares in Q1 2026, an estimated $916K.
  • Collegium Pharmaceutical made up 0.09% of Royce & Associates's portfolio in Q1 2026, its #360 holding.
  • Royce & Associates first reported a position in Collegium Pharmaceutical in Q4 2017 and has held it in 24 quarters since.
  • Royce & Associates's Collegium Pharmaceutical position peaked at $11.8M in Q3 2024.
  • 266 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q1 2026.

Based on Royce & Associates's 13F filing for Q1 2026, filed 12 May 2026.